Researchers at MIT found that short bursts of pink noise during sleep can increase the amplitude of slow electrical waves and CSF flow, leading to more restorative sleep. This technology may also help clear brain waste and potentially improve cognitive function, particularly in people with insomnia and neurodegenerative diseases.
The Lasker Foundation has announced the 2026 Lasker Award winners, honoring fundamental discoveries in sleep research, revolutionary therapy for hemophilia A, and leadership in Parkinson’s disease research advocacy. Emmanuel Mignot and Masashi Yanagisawa will receive the Albert Lasker Basic Medical Research Award for discovering orexin...
A. Campbell Sullivan, a neuropsychologist, discovered a gap between treatment and science of ALS and dementia in her own family. She notes that advances in genetics and biomarker discovery are transforming research and care in ALS and FTD.
Researchers at Barrow Neurological Institute discovered a link between wildfire smoke and neurodegenerative diseases like Parkinson's and Alzheimer's. Wildfire smoke particles activate astrocytes, leading to inflammation and damage to nearby brain cells.
A cohort study found that only 30.7% of brain donors with clinician-adjudicated dementia had neurodegenerative death certification. The study suggests factors like worsening cognitive symptoms and functional impairment may be associated with increased likelihood of neurodegenerative death certification.
Researchers develop a polymer nanogel system called Nano-ERASER that uses antibodies to degrade targeted proteins, inducing neuron regeneration and restoring neural circuits in human brain organoids and mice with Alzheimer's disease. The study provides a critical step in regenerative neuroscience, offering a roadmap for a potential cure.
A study finds that dementia with Lewy bodies preferentially affects certain brain regions, including those with genes linked to mitochondrial function and synapses. These regions show distinctive patterns of serotonin, dopamine, and GABA receptors, suggesting a potential target for new treatments.
Research identifies aberrant ERBB4 expression in excitatory neurons as an early driver of Alzheimer's disease pathologies, including neuronal hyperactivity, synapse loss, and cognitive decline. Manipulating ERBB4 expression in mouse models reveals its role in driving disease features, including reactive gliosis and amyloid buildup.
Jeffery Kelly, a Scripps Research professor, has been elected to the European Academy of Engineering for his groundbreaking research on protein folding and its link to diseases. His work led to the development of FDA-approved therapeutics for amyloid polyneuropathy and cardiomyopathy.
A new study published in The BMJ found that nearly a quarter of former NFL players who died from 2016 to 2021 had confirmed CTE, with stage IV CTE linked to symptoms typical of dementia. The study provides one of the most informative estimates to date of CTE burden among former NFL players.
The publication of the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker highlights a decade of collaborative progress in biomarker development. This milestone enables earlier testing of new treatments for Parkinson's disease, which could delay or prevent disease onset and progression.
Salk Institute researchers found microglia's novel way to contribute to ALS progression and death, using TAM receptors to find and kill motor neurons in spinal cords of mice with ALS. The study suggests a new target for therapy innovation, but notes the complexity of variables involved.
Researchers review evidence on potential transmission of amyloid-beta and CAA through blood transfusions, citing a 2023 study that found recipients of contaminated blood had a higher risk of brain bleeds. The authors argue for additional safety measures, citing a cautionary tale from the Infected Blood Inquiry.
Researchers have discovered a gene linked to Parkinson's disease may also strengthen the body's ability to fight dangerous infections. The study found that a well-studied mutation in the LRRK2 gene increases the production of reactive oxygen species, making immune cells more effective at eliminating intracellular bacteria.
A study confirms the 20-item prosopagnosia index questionnaire is an effective screening tool for detecting developmental prosopagnosia, a condition where individuals struggle to recognize familiar faces. The researchers also identified opportunities for refinement to improve the questionnaire's accuracy.
A nationwide study found that people living within 500 feet of dry cleaners had a 14% greater risk of developing Parkinson's disease compared to those living further away. The study, led by Barrow Neurological Institute, highlights the potential role of environmental exposures in disease development.
Researchers found that healthier superficial white matter is associated with stronger language skills, and that gray matter atrophy measures remain the strongest predictors of cognition. However, the relationship between gray matter and cognitive performance depends on superficial white matter health.
Researchers have discovered lymph node-like structures in the skull bone marrow of mice that act as rapid first responders against brain cancer and neurodegenerative diseases. The discovery offers a new way to fight brain cancer and other neurological diseases.
Researchers discovered how anesthesia, surgery, and intensive care stress alter gene activity in the brain, leading to cognitive impairment and delirium. A new drug, vorinostat, reversed these changes, restoring memory formation and regulating the internal biological clock.
Researchers from the University of Osaka developed an analytical tool called acoustic tweezers to investigate the mechanical properties of biopolymer condensates. The study found that changes in the natural movement of a droplet in solution can provide information on the stiffness of the droplet and the state of the molecules inside.
Researchers identified TIMP2 as a key factor supporting healthy microglial function in the aging brain. Restoring TIMP2 in aged mice improved microglia's ability to clear debris and reduced inflammation, suggesting potential therapeutic strategies for neurodegenerative disorders.
According to a national survey commissioned by The Ohio State University Wexner Medical Center, most U.S. adults believe brain health habits should begin before age 40. Regular exercise, quality sleep, healthy eating, and strong social connections can help support long-term brain health.
Researchers developed a novel imaging approach called SANDI to study microstructural brain abnormalities associated with Huntington's disease. The model revealed differences in cell density and size, correlating with disease progression and motor performance.
Researchers at UC San Diego identified a key cellular pathway that drives brain degeneration in both Sanfilippo syndrome type A and Alzheimer's disease. The study reveals how the brain's immune cells respond to waste buildup, providing a novel target for drug development.
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Researchers at Weill Cornell Medicine have identified structural changes that enable the LRRK2 protein to become overactive, a key step in Parkinson's disease progression. Understanding these changes is crucial for developing targeted therapies to slow or halt the disease.
Researchers found that exercise-induced molecular changes contribute to neuronal health, improving movement and quality of life in PD patients. Exercise types such as aerobic exercises, resistance training, balance training, and multimodal exercise were found to be helpful in reducing falls, disabilities, and improving brain function.
The first complete marmoset genome is now available, providing a high-quality reference for studying complex diseases like Alzheimer's. The new genome reveals variation in genes linked to Alzheimer's disease, as well as immune system genes and previously un-catalogued ribosomal DNA genes.
A study by Stanford Medicine scientists reveals that wayward tau molecules can gum up mitochondria's internal energy-production lines, initiating a vicious cycle of pathological events. This discovery provides a new mechanism driving tauopathies and renders these disorders amenable to new therapeutic interventions.
Researchers at Stanford University discovered that aging brings a large influx of immune cells into the brain, upending previous assumptions about the brain's immune system. The study suggests that these immune cells may interact with the brain and contribute to its resilience against Alzheimer's disease.
Researchers used real human brain tissue samples to test the underlying mechanisms of deep brain stimulation. They found that brain cells became more synchronized in communicating, similar to memory formation, while altering gene expression across different types of brain cells.
The Boston University-Quantitative Population Science and Healthy Cognitive Aging Research Program (BU-SHARP) aims to better understand how and why Alzheimer's disease manifests among certain populations. The center will fund pilot studies, provide technical assistance, and facilitate access to underutilized datasets.
A new report finds that delayed discharges and poor hospital environments keep people with dementia in hospitals unnecessarily, costing £328 million annually. The study suggests community-centric approaches can reduce hospitalisations and improve care.
A new USC study uses AI to generate detailed maps of brain aging, revealing distinct patterns of neurodegeneration in specific regions. The approach sheds light on how local brain age correlates with changes in cognitive function across the lifespan.
Researchers have identified a new type of brain plaque, called mitochondrial plaques, that may emerge at the earliest stages of Alzheimer's disease. These plaques contain high levels of amyloid precursor protein and can directly affect neurons, making them a potential target for new treatments.
Researchers at the University of Illinois developed a gene editing tool to treat Huntington's disease by altering a specific point in the huntingtin gene. The treatment reduced toxic protein fragments, symptoms, and brain degeneration in mice, providing a new approach for treating genetic diseases.
Researchers have identified a panel of key proteins in blood that can predict the emergence of ALS symptoms months to years before they arise. This discovery could enable early intervention with preventative therapies.
A study found that brain immune cells undergo substantial remodeling in midlife, leading to chronic neuroinflammation and potential dementia risk. The research used advanced single-cell analysis techniques to analyze postmortem hippocampal tissue from 40 healthy adults.
Researchers developed a new methodology using artificial intelligence to analyze brain electrical activity during sleep, identifying early neural alterations and classifying patients into distinct biological subgroups. This non-invasive approach may facilitate earlier diagnosis of Alzheimer's disease.
Researchers identify a specialized lymphatic network in the brain that enables cerebrospinal fluid drainage, which declines with age but can be restored through intranasal VEGF-C delivery. This discovery provides new insights into brain waste clearance and its link to neurodegenerative disorders.
Researchers found that bee venom can improve motor function and cognitive decline in a mouse model of Parkinson's disease when used alongside conventional therapy. The study suggests promising benefits for developing adjunct therapies to improve treatment outcomes.
A new study by Sanford Burnham Prebys found that bolstering the SORLA protein can reduce tau tangle toxicity, a common culprit in Alzheimer's disease and other neurodegenerative disorders. This suggests potential as a therapeutic strategy for treating these conditions.
Researchers found that tau buildup in PSP affects brain networks involved in thinking, including the prefrontal cortex and anterior cingulate cortex. The study suggests that symptoms arise from both local tau-related damage and remote disruption of a broader cognitive network.
Researchers at Kyoto University discovered an RNA aptamer, 1R6, that targets the disordered regions of alpha-synuclein protein, inhibiting its aggregation and promoting disassembly of pre-existing aggregates. This finding offers a new therapeutic strategy for neurodegenerative disorders like Parkinson's disease.
A scoping review suggests astrocytic dysfunction may precede neuronal degeneration in CTE. Astrocytes' dysregulation contributes to the development of CTE's characteristic features through mechanisms including astrogliosis, disrupted waste clearance pathways, and chronic neuroinflammation.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
A blood test measuring phosphorylated tau 217 (P-tau217) can estimate an individual's risk of developing cognitive impairment over 2, 5, and 10 years. Higher P-tau217 levels are associated with increased risk of progression to cognitive impairment in cognitively unimpaired older adults.
Researchers discovered that reducing microglial activity worsened abnormal electrical activity and increased seizure-like events in a mouse model of Alzheimer's disease. Microglia are not just drivers of inflammation but also perform important housekeeping functions to maintain healthy brain activity.
The University of Cincinnati launches the Center for Alzheimer's and Neurodegenerative Diseases Research (CANDR) to improve dementia prevention and treatment outcomes. CANDR aligns with UC's mission to innovate and engage locally while addressing one of the region's most pressing public health challenges.
A new study published in the Journal of Alzheimer's Disease estimates that dementia-related costs across 30 high-income European countries total €221 billion annually. Family caregivers carry a significant portion of this burden, providing an estimated €128 billion in unpaid care.
A University of Houston chemist is uncovering how copper imbalances in neurons contribute to neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. The new imaging technique provides a closer look at individual protein behaviors inside living cells, giving researchers insight into the cellular pathways that fail.
A large USC study of over 214,000 older adults across 14 countries found that controllable dementia risk factors such as low education and high blood pressure differ significantly from country to country. The study's findings suggest a one-size-fits-all approach to prevention may not be effective everywhere, and highlight the importanc...
Researchers discovered that damaged myelin generates abnormal rhythms in the sleeping brain, linked to disruptions in brain circuit stability. This finding may help design non-invasive approaches to repair myelin during sleep, improving sleep quality in patients with MS and Alzheimer's disease.
The STEM-PD trial demonstrated the safety and feasibility of stem cell-derived dopaminergic cell transplantation in patients with moderate to advanced Parkinson's disease. The findings mark an important step in evaluating this approach as a potential treatment strategy for neurodegenerative diseases.
A new $250,000 grant will support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction. The treatment aims to protect the brain from inflammation-related damage during and after sepsis, potentially preventing or slowing neurodegeneration and cognitive decline.
Researchers at ISSCR 2026 present interim clinical findings from the first Phase 1/2a trial of autologous iPSC-derived dopamine neuron precursor cells for Parkinson's disease. The approach uses each patient's own cells, and new genomic quality control methods ensure the manufactured cells are suitable for transplantation.
The University of California, San Francisco is launching a novel clinical trial to test a combination of therapies for the most common form of Alzheimer's disease. The trial will enroll up to 825 participants and test drugs that target both amyloid and tau proteins, with the goal of slowing disease progression.
The REGEN4HD study marks a significant milestone in the development of regenerative medicine approaches for Huntington's disease. The Phase 1b/2a trial enrolls early-stage symptomatic patients to evaluate safety and tolerability.
Research suggests alcohol interacts with Alzheimer's-related brain circuits in distinct ways, depending on the type of pathological change. Alcohol reduced communication in amyloid-beta models but increased it in tau models, highlighting an important principle in biology.
Researchers found that KCL-286 enhances DNA repair and reduces neuronal inflammation in a mouse model of Alzheimer's disease. The drug activates the retinoic acid receptor-beta pathway, promoting the expression of certain repair genes.